A mild trend toward PFS benefit under the combined regimen was also noted in patients with brain metastases and first-line treatment, though not reaching statistical significance.
← all excerpts
Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.
2
—
—
The sentences
Similarly, our study showed a slight trend toward PFS benefit for patients receiving combination therapy as first-line treatment (HR = 0.84, 95% CI: 0.54–1.30).